NICE TAs

13/08/2020

TA283: Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion

12/08/2020

TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation

12/08/2020

TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours

12/08/2020

TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus.

12/08/2020

TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer

12/08/2020

NG28: Type 2 diabetes in adults: management

12/08/2020

TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

12/08/2020

TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (replaced TA255)

12/08/2020

TA644: Entrectinib for treating NTRK fusion-positive solid tumours

12/08/2020

TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer

12/08/2020

TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia

12/08/2020

TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma

11/08/2020

TA276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

11/08/2020

TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

11/08/2020

TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

11/08/2020

TA267: Ivabradine for treating chronic heart failure

11/08/2020

TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

11/08/2020

TA266: Mannitol dry powder for inhalation for treating cystic fibrosis

11/08/2020

TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer

11/08/2020

TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (replaced TA271)